Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM2 | P08172 | 4/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 4/20 | 0.42 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.42 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 2/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10223569 | 0.83 | CHRM2 (0.40) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL13740334 | 0.77 | CHRM2 (0.41) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL9022380 | 0.72 | CHRM2 (0.71) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL858699 | 0.72 | DPP4 (0.59) | DPP4DPP8DPP9 | |
| SCHEMBL26094394 | 0.72 | DPP4 (0.59) | DPP4DPP8DPP9 | |
| SCHEMBL10223539 | 0.72 | — | — | |
| SCHEMBL3526616 | 0.72 | DPP4 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL6234921 | 0.72 | DPP4 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL3601162 | 0.72 | DPP4 (0.39) | CHRM2CHRM4CHRM5CHRM1CHRM3 | |
| SCHEMBL5314581 | 0.72 | DPP4 (0.59) | DPP4DPP8DPP9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2400846-A1 | HEPATITIS C VIRUS INHIBITORS | Enanta Pharmaceuticals, Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABBOTT LABORATORIES | 2005-02-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026944-A1 | Thienopyridine and furopyridine kinase inhibitors | ABL1, ERBB2, LCK | CHRM2 4208/4885CHRM4 4443/4885CHRM5 4338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.